BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 32542437)

  • 1. Immune suppression in gliomas.
    Grabowski MM; Sankey EW; Ryan KJ; Chongsathidkiet P; Lorrey SJ; Wilkinson DS; Fecci PE
    J Neurooncol; 2021 Jan; 151(1):3-12. PubMed ID: 32542437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune microenvironment of gliomas.
    Gieryng A; Pszczolkowska D; Walentynowicz KA; Rajan WD; Kaminska B
    Lab Invest; 2017 May; 97(5):498-518. PubMed ID: 28287634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of myeloid cells in the immunosuppressive microenvironment in gliomas.
    Locarno CV; Simonelli M; Carenza C; Capucetti A; Stanzani E; Lorenzi E; Persico P; Della Bella S; Passoni L; Mavilio D; Bonecchi R; Locati M; Savino B
    Immunobiology; 2020 Jan; 225(1):151853. PubMed ID: 31703822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-derived extracellular vesicles: how they mediate glioma immunosuppression.
    Ma T; Su G; Wu Q; Shen M; Feng X; Zhang Z
    Mol Biol Rep; 2024 Jan; 51(1):235. PubMed ID: 38282090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Myeloid Cells in GBM Immunosuppression.
    Lin YJ; Wu CY; Wu JY; Lim M
    Front Immunol; 2022; 13():887781. PubMed ID: 35711434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The immunosuppressive microenvironment of malignant gliomas].
    Borisov KE; Sakaeva DD
    Arkh Patol; 2015; 77(6):54-63. PubMed ID: 26841651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion.
    Pinton L; Masetto E; Vettore M; Solito S; Magri S; D'Andolfi M; Del Bianco P; Lollo G; Benoit JP; Okada H; Diaz A; Della Puppa A; Mandruzzato S
    J Immunother Cancer; 2019 Feb; 7(1):58. PubMed ID: 30813960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic and local immunosuppression in glioblastoma and its prognostic significance.
    Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Pavlov KA; Chekhonin VP
    Front Immunol; 2024; 15():1326753. PubMed ID: 38481999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When Immune Cells Turn Bad-Tumor-Associated Microglia/Macrophages in Glioma.
    Roesch S; Rapp C; Dettling S; Herold-Mende C
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29389898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma.
    Chen Q; Han B; Meng X; Duan C; Yang C; Wu Z; Magafurov D; Zhao S; Safin S; Jiang C; Cai J
    Int J Cancer; 2019 Jul; 145(2):517-530. PubMed ID: 30613962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas.
    Zeiner PS; Preusse C; Golebiewska A; Zinke J; Iriondo A; Muller A; Kaoma T; Filipski K; Müller-Eschner M; Bernatz S; Blank AE; Baumgarten P; Ilina E; Grote A; Hansmann ML; Verhoff MA; Franz K; Feuerhake F; Steinbach JP; Wischhusen J; Stenzel W; Niclou SP; Harter PN; Mittelbronn M
    Brain Pathol; 2019 Jul; 29(4):513-529. PubMed ID: 30506802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy.
    Mishchenko TA; Turubanova VD; Gorshkova EN; Krysko O; Vedunova MV; Krysko DV
    Front Immunol; 2023; 14():1299064. PubMed ID: 38274827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microglia-glioma cross-talk: a two way approach to new strategies against glioma.
    Arcuri C; Fioretti B; Bianchi R; Mecca C; Tubaro C; Beccari T; Franciolini F; Giambanco I; Donato R
    Front Biosci (Landmark Ed); 2017 Jan; 22(2):268-309. PubMed ID: 27814616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.
    Kwok D; Okada H
    J Neurooncol; 2020 Apr; 147(2):281-295. PubMed ID: 32185647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment.
    Müller S; Kohanbash G; Liu SJ; Alvarado B; Carrera D; Bhaduri A; Watchmaker PB; Yagnik G; Di Lullo E; Malatesta M; Amankulor NM; Kriegstein AR; Lim DA; Aghi M; Okada H; Diaz A
    Genome Biol; 2017 Dec; 18(1):234. PubMed ID: 29262845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune microenvironment of experimental rat C6 gliomas resembles human glioblastomas.
    Gieryng A; Pszczolkowska D; Bocian K; Dabrowski M; Rajan WD; Kloss M; Mieczkowski J; Kaminska B
    Sci Rep; 2017 Dec; 7(1):17556. PubMed ID: 29242629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
    Lakshmanachetty S; Cruz-Cruz J; Hoffmeyer E; Cole AP; Mitra SS
    Cells; 2021 Apr; 10(4):. PubMed ID: 33919732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on Microglia-Based Immune Therapies Against Glioblastoma.
    Rivera M; Bander ED; Cisse B
    World Neurosurg; 2021 Oct; 154():228-231. PubMed ID: 34583500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioma-associated microglia/macrophages (GAMs) in glioblastoma: Immune function in the tumor microenvironment and implications for immunotherapy.
    Lin C; Wang N; Xu C
    Front Immunol; 2023; 14():1123853. PubMed ID: 36969167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
    Pachocki CJ; Hol EM
    J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.